Further to the announcement on 6 January 2021 to postpone the appeal hearing for the appraisal of Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531], we are now able to confirm the new dates for the hearing. The appeal hearing to hear oral representations from the appellants will be held on Thursday 4 and Friday 5 March 2021 on Zoom.

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. Registration to observe the hearing is available on our website from Friday 5 February 2021 until 4pm on Friday 26 February 2021.

NICE received three valid appeals against the FAD for this technology appraisal from Pfizer, British Society for Heart Failure and Cardiomyopathy UK.




This page was last updated: